Skip to main content

biote (NASDAQ: BTMD) — Company Overview, News & Financial Data

biote  logo
BTMD biote
biote  primary media
Company profile

biote

Biote (NASDAQ:BTMD) specializes in hormone optimization and personalized healthcare solutions, focusing on addressing hormonal imbalances through bio-identical hormone replacement therapy (BHRT). With a patient-centered approach, Biote aims to enhance the quality of life for individuals by offering tailored treatment plans that address a wide range of hormonal issues. Their projects extend into research and development of new protocols for hormone optimization, aiming to set new standards in personalized medicine. Biote's objectives are to expand its market reach, continuously improve patient outcomes through innovative therapies, and contribute to the broader understanding of hormone-related health conditions.

Snapshot

Public USOwnership
2012Year founded
194Employees
Irving, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Irving, US

Products and/or services of biote

  • Hormone optimization therapies, focusing on balancing hormones to improve patient health and wellbeing.
  • Bioidentical hormone replacement therapy (BHRT) pellets, a natural approach to addressing hormone imbalances.
  • Personalized hormone optimization plans, tailored to individual patient needs for comprehensive healthcare.
  • Nutraceuticals line, offering supplements to support hormone health and overall wellness.
  • Educational resources for practitioners, enhancing understanding of hormone optimization and BHRT.
  • Partnership programs with healthcare providers, expanding access to hormone optimization treatments.

biote executive team

  • Marc D. BeerExecutive Chairman
  • Robert C. PetersonInterim CEO, CFO & Chief Business Officer
  • John J. OlsenChief Information Officer
  • Dan MonicoGeneral Counsel
  • Richard Kevin KeyChief Digital Officer
  • Jade BeutlerHead of Nutraceuticals
  • Cory RiceChief Clinical Advisor & Member of Medical Advisory Board
  • Joey LopesSVP of Strategy & Commercial Operations
  • Komal BajajChief Medical Officer

Recent announcements

What biote (BTMD) has told the market, newest first.

Key financials

Reported results for biote , in USD.

Market cap
27M
Revenue (TTM)
178.9M
P/E ratio
—
EPS (diluted, TTM)
-0.1
Dividend yield
—
Profit margin
-1.1%
biote annual revenue and income
Fiscal year endRevenueOperating incomeNet income
192.2M35.6M27M
197.2M31.6M3.2M
185.4M28.7M3.3M
165M-60.7M-969K